These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38943371)

  • 21. Maximizing treatment outcome: key considerations for antiretroviral-experienced patients.
    Witek J
    AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S19-25. PubMed ID: 19960653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of genotypic resistance testing on physician selection of antiretroviral therapy.
    Jones S; Klotman ME
    J Hum Virol; 2001; 4(4):214-6. PubMed ID: 11694849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
    Fusco P; Nasta P; Quiros-Roldan E; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112904
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of antiretroviral regimen switches on adherence.
    Miller LG; Golin CE; Hays RD; Liu H; Beck CK; Kaplan AH; Wenger NS
    HIV Clin Trials; 2002; 3(5):355-60. PubMed ID: 12407484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of antiretroviral therapy in the single-tablet regimen era.
    Costa JO; Ceccato MDGB; Silveira MR; Bonolo PF; Reis EA; Acurcio FA
    Rev Saude Publica; 2018 Nov; 52():87. PubMed ID: 30462751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen.
    Turner BJ; Zhang D; Laine C; Pomerantz RJ; Cosler L; Hauck WW
    J Acquir Immune Defic Syndr; 2001 May; 27(1):20-9. PubMed ID: 11404516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durability of adherence to antiretroviral therapy on initial and subsequent regimens.
    Gardner EM; Burman WJ; Maravi ME; Davidson AJ
    AIDS Patient Care STDS; 2006 Sep; 20(9):628-36. PubMed ID: 16987049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios.
    Huesgen E; DeSear KE; Egelund EF; Smith R; Max B; Janelle J
    Pharmacotherapy; 2016 Nov; 36(11):1145-1165. PubMed ID: 27636237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
    Brogan AJ; Smets E; Mauskopf JA; Manuel SA; Adriaenssen I
    Pharmacoeconomics; 2014 Sep; 32(9):903-17. PubMed ID: 24906477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost considerations in the current antiretroviral era.
    Eaton EF; Tamhane A; Saag M; Mugavero MJ; Kilgore ML
    AIDS; 2016 Sep; 30(14):2115-9. PubMed ID: 27088319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral treatment in pregnancy.
    Anderson JR
    Hopkins HIV Rep; 1998 May; 10(3):6-7, 10. PubMed ID: 11365495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood Products.
    Kawado M; Hashimoto S; Oka SI; Fukutake K; Higasa S; Yatsuhashi H; Ogane M; Okamoto M; Shirasaka T
    Open AIDS J; 2017; 11():18-23. PubMed ID: 28553428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnitude and causes of first-line antiretroviral therapy regimen changes among HIV patients in Ethiopia: a systematic review and meta-analysis.
    Ataro Z; Motbaynor B; Weldegebreal F; Sisay M; Tesfa T; Mitiku H; Marami D; Teklemariam Z; Shewamene Z
    BMC Pharmacol Toxicol; 2019 Nov; 20(1):63. PubMed ID: 31675986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
    Chan DJ; Ray JE; McNally L; Batterham M; Smith DE
    Curr HIV Res; 2008 Sep; 6(5):477-84. PubMed ID: 18855660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to first positive HIV-1 DNA PCR may differ with antiretroviral regimen in infants infected with non-B subtype HIV-1.
    Balasubramanian R; Fowler MG; Dominguez K; Lockman S; Tookey PA; Huong NNG; Nesheim S; Hughes MD; Lallemant M; Tosswill J; Shaffer N; Sherman G; Palumbo P; Shapiro DE
    AIDS; 2017 Nov; 31(18):2465-2474. PubMed ID: 28926397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z
    BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.